PubMed

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH.

Ann Intern Med. 2009 Jul 7;151(1):11-20, W3-4. Epub 2009 May 18.PMID: 19451554 [PubMed - indexed for MEDLINE]Related articles

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1394-402. Epub 2008 Sep 25.PMID: 18823656 [PubMed - indexed for MEDLINE]Related articles

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.PMID: 16095545 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.

Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E; CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators.

J Hypertens. 2005 Feb;23(2):435-44.PMID: 15662233 [PubMed - indexed for MEDLINE]Related articles

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1385-93. Epub 2008 Sep 25.PMID: 18823658 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

Ann Intern Med. 2003 Apr 1;138(7):542-9.PMID: 12667024 [PubMed - indexed for MEDLINE]Related articlesFree article

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.PMID: 14586737 [PubMed - indexed for MEDLINE]Related articles

Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.

Sato A, Tabata M, Hayashi K, Saruta T.

Clin Exp Nephrol. 2003 Sep;7(3):215-20.PMID: 14586718 [PubMed - indexed for MEDLINE]Related articles

The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial.

Perrin NE, Jaremko GA, Berg UB.

Pediatr Nephrol. 2008 Jun;23(6):947-54.PMID: 18270751 [PubMed - indexed for MEDLINE]Related articles

The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics.

Sjølie AK, Porta M, Parving HH, Bilous R, Klein R; DIRECT Programme Study Group.

J Renin Angiotensin Aldosterone Syst. 2005 Mar;6(1):25-32.PMID: 16088848 [PubMed - indexed for MEDLINE]Related articles

Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.

Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.

Nephrol Dial Transplant. 2006 Mar;21(3):683-9. Epub 2005 Dec 5.PMID: 16330466 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME.

BMJ. 2000 Dec 9;321(7274):1440-4.PMID: 11110735 [PubMed - indexed for MEDLINE]Related articlesFree article

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators.

Am J Kidney Dis. 2005 Mar;45(3):485-93.PMID: 15754270 [PubMed - indexed for MEDLINE]Related articles

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data.

ACE Inhibitors in Diabetic Nephropathy Trialist Group.

Ann Intern Med. 2001 Mar 6;134(5):370-9.PMID: 11242497 [PubMed - indexed for MEDLINE]Related articlesFree article

Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.

Fogari R, Corradi L, Zoppi A, Lazzari P, Mugellini A, Preti P, Rinaldi A.

Am J Hypertens. 2007 Oct;20(10):1092-6.PMID: 17903693 [PubMed - indexed for MEDLINE]Related articles

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.

N Engl J Med. 2001 Sep 20;345(12):870-8.PMID: 11565519 [PubMed - indexed for MEDLINE]Related articlesFree article

Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.

Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH.

Diabetes Care. 2003 Jan;26(1):150-5.PMID: 12502672 [PubMed - indexed for MEDLINE]Related articlesFree article

[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting]

Lehnert H, Bramlage P, Pittrow D, Kirch W.

MMW Fortschr Med. 2003 Oct 9;145 Suppl 3:81-7. German. PMID: 15490772 [PubMed - indexed for MEDLINE]Related articles

The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.

Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.

Clin Nephrol. 2003 Nov;60(5):318-26.PMID: 14640237 [PubMed - indexed for MEDLINE]Related articles

Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.

Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S; INNOVATION Study Group.

Hypertens Res. 2008 Apr;31(4):657-64.PMID: 18633177 [PubMed - indexed for MEDLINE]Related articles